CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 6 enrolled
Drug / intervention
[18F]GTP1other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04394845
NCT04394845Phase 1Completed
CompareCT.gov

Assessment of the Biodistribution and Safety of [18F]GTP1 in Healthy Japanese Subjects

Genentech, Inc.·interventional·Posted May 19, 2020·Updated Nov 3, 2021

In Brief

A Phase 1 clinical trial evaluating [18F]GTP1 for Alzheimer Disease. Completed, enrolled 6 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the biodistribution, safety and tolerability of a single dose of \[18F\]GTP1 as a tau targeted radiopharmaceutical in healthy Japanese participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
CollaboratorsInvicro

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedMay 19, 2020
Enrollment StartAug 11, 2020
Primary CompletionOct 9, 2020
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 6.1 years ago

Interventions

[18F]GTP1other

\[18F\]GTP1 IV bolus injection of up to 370 megabecquerel (MBq) (10 millicurie \[mCi\]), with a maximum drug mass dose of 10 microgram (μg).